Advertisement Ranbaxy settles patent litigation with GlaxoSmithKline - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Ranbaxy settles patent litigation with GlaxoSmithKline

Ranbaxy Laboratories has settled all matters relating to possible patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline's Imitrex tablets.

The terms of the settlement provide that Ranbaxy may distribute a generic version of sumatriptan succinate tablets (in the 25mg, 50mg and 100mg strengths) in the US with an expected launch date in December, 2008.